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Complex bispecific and novel molecules are increasingly being developed as therapeutic proteins. These 
molecules present challenges for the generation of high quality manufacturing cell lines with good productivity 
and desirable product quality.  High aggregation, poor sialylation and multiple chain mispairing are three of the 
major product quality problems affecting these molecules. To address these issues, we have developed a new 
expression platform which has been combined with high throughput analytical assays to screen and select 
clones with the preferred product quality profiles.  Case studies will be presented on the development of cell 
lines expressing two types of bispecific molecules. To address the high level of aggregation observed with a 
bispecific molecule, the underlying cause of aggregation has been investigated and vector engineering tools 
have been applied to manipulate the expression of specific subunits of the protein leading to reduced 
aggregation. For another monomeric bispecific project, cell lines expressing four different polypeptides are 
generated and then efficiently screening at early stages of development to identify those with a high proportion 
of correctly assembled protein. These results also provide valuable information to assist in the molecular design 
and protein engineering of bispecific molecules.  
 
 
